ASCO Annual Meeting 2024
Experts across clinical, medical affairs, and commercial are working hard every day to de-risk drug development by leveraging experience, insights and capabilities that offer thoughtful, integrated solutions. In pursuing new products to help cancer patients see better outcomes, there are inherent, unique challenges and considerations. Customers leverage our experience, insights and capabilities every day to overcome these challenges and achieve more efficient oncology drug development.
Meet with us at ASCO to discuss how we can help you balance the excitement of innovation against the operational realities of bringing complex therapies to cancer patients.
Our Attendees
Daniel Mazzolenis, MD, MBA | Senior Vice President of Medical Management
Wael A Harb, MD | Vice President of Medical Affairs
Patrick Kelly, MD | Vice President of Medical Management
Patrick Melvin | Vice President, Novel and Emerging Therapies, TA Lead, Hematology/Oncology
Related Content:
Vous voulez en savoir plus? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
Three Lessons Learned in Adoptive Cell Therapy Trials: A Look at the Road Ahead for Immunology
Time & Motion Studies at Syneos Health
Exploring an Expedited Regulatory Pathway for Cell and Gene Therapies
Syneos Health Podcast, APAC Edition | Radiosensitizers in Head and Neck Cancers
